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Somatic RUNX1 mutations are found in approximately 10% 
of patients with de novo acute myeloid leukemia (AML), but 
are more common in secondary forms of myelodysplastic 
syndrome (MDS) or AML. Particularly, this applies to 
MDS/AML developing from certain types of leukemia-prone 
inherited bone marrow failure syndromes. How these RUNX1 
mutations contribute to the pathobiology of secondary 
MDS/AML is still unknown. This mini-review focusses on the 
role of RUNX1 mutations as the most common secondary 
leukemogenic hit in MDS/AML evolving from severe 
congenital neutropenia (SCN).  
Keywords: leukemic progression, RUNX1, severe congenital 
neutropenia
INTRODUCTION 
The occurrence and frequency of RUNX1 mutations in a 
variety of hematological malignancies has been well-docu-
mented (Sood et al., 2017). Originally identified as a chro-
mosomal translocation partner in the so-called core-binding 
factor (CBF) leukemias, somatic RUNX1 mutations were also 
found in myeloid malignancies, particularly in myelodysplastic 
syndrome (MDS) and acute myeloid leukemia (AML) (Chen 
et al., 2007; Christiansen et al., 2004; Gaidzik et al., 2011; 
Harada et al., 2004; Mangan and Speck, 2011; Osato, 2004; 
Schnittger et al., 2011; Steensma et al., 2005; Tang et al., 
2009). Somatic mutations in RUNX1 cluster mostly within the 
N-terminal Runt homology domain (RHD) whereas mutations 
disrupting the C-terminal transactivation domain (TAD) oc-
cur less frequently (Gaidzik et al., 2011; Preudhomme et al., 
2000; Schnittger et al., 2011; Tang et al., 2009). Importantly, 
mutations in RUNX1 were identified as the cause of familial 
platelet disorder, in which patients show a predisposition to 
develop MDS or AML (FPDMM or FPD/AML) (Song et al., 
1999). These germline mutations are similar to those ac-
quired in MDS/AML (Song et al., 1999). Finally, it has become 
clear that somatic RUNX1 mutations are particularly prevalent 
in MDS/AML secondary to inherited bone marrow failure 
syndromes (iBMFs) such as Fanconi anemia and severe con-
genital neutropenia (SCN), and in radiation-associated MDS/
AML (Harada et al., 2003; Quentin et al., 2011; Skokowa 
et al., 2014). These forms of secondary MDS/AML (sMDS/
AML) are characterized by an adverse prognosis due to re-
fractoriness to treatment. Why secondary RUNX1 mutations 
are associated with sMDS/AML and how they contribute to 
the pathogenesis of these conditions remains largely unclear. 
Here, we will discuss the current insights and ideas regarding 
mutant RUNX1 in the context of malignant transformation 
of iBMFs, taking SCN as the leading example. Specifically, we 
will briefly summarize and discuss our most recent insights 
into these issues based on observations in patients, mouse- 
and induced pluripotent stem cell (iPSC)-models. 
SEVERE CONGENITAL NEUTROPENIA
SCN is an iBMF characterized by severely reduced neutro-
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phil counts, leading to life-threatening bacterial infections 
(Skokowa et al., 2017). Autosomal dominant mutations in 
ELANE, the gene encoding neutrophil elastase, are the most 
frequently observed genetic defects in SCN patients. How 
these mutations give rise to severe neutropenia is still largely 
unknown (Skokowa et al., 2017). Life-long administration of 
colony stimulating factor 3 (CSF3), also known as granulo-
cyte colony-stimulating factor (G-CSF), successfully alleviates 
the neutropenia in the majority of SCN patients (Dale et al., 
1993). Importantly, SCN patients have a high risk of develop-
ing MDS or AML, with a median incidence of 21%, 15 years 
after initiation of CSF3 treatment (Rosenberg et al., 2006; 
2010). The majority of SCN patients with leukemic progres-
sion show the appearance of hematopoietic clones with 
somatic mutations in CSF3R, resulting in a truncated form of 
CSF3R with defective internalization and aberrant signaling 
properties (Touw, 2015). These clones may persist for months 
or even years before MDS or AML becomes overt (Germe-
shausen et al., 2007), raising the question how these CSF3R 
mutants contribute to the malignant transformation of SCN. 
Activation of oxidative stress through enhanced production 
of reactive oxygen species (ROS) and sustained activation of 
signal transducer and activator of transcription STAT5 have 
been put forward as candidate mechanisms by which acti-
vation of truncated CSF3R drive clonal expansion of myeloid 
progenitors (Liu et al., 2008; Zhu et al., 2006).
RUNX1 MUTATIONS IN SCN-MDS/AML PATIENTS 
Like for numerous other disease conditions, the introduction 
of massive parallel (“next generation”) sequencing has greatly 
advanced our insights into the genomic defects associated 
with the leukemic progression of SCN. A retrospective anal-
ysis in an ELANE-SCN patient, who continuously received 
CSF3 therapy for 15 years and during which period serial BM 
sampling was done, showed that after the occurrence of 
multiple CSF3R mutant clones 2 years after the start of CSF3 
treatment, no additional mutations were detected until MDS/
AML became clinically overt (Beekman et al., 2012). At that 
fully transformed stage, a limited number of clonal mutations 
in regulatory genes, including RUNX1, SUZ12, ASXL1 and 
EP300, were present (Beekman et al., 2012). This pattern of 
leukemic evolution was confirmed in a follow-up study involv-
ing 31 SCN-MDS/AML cases (Skokowa et al., 2014). Impor-
tantly, this study revealed that mutations in RUNX1 are by far 
the most frequent somatic secondary mutations in SCN-MDS/
AML and preferentially occurred in CSF3R mutation clones. 
In SCN-MDS/AML, mainly RUNX1 mutations disrupting the 
RHD, essential for DNA binding and for interaction with the 
regulatory protein CBFβ, were found (Beekman et al., 2012; 
Skokowa et al., 2014). In view of these characteristics, the 
molecular pathogenesis of SCN/AML serves as an attractive 
model to investigate the role of secondary RUNX1 mutations 
in a molecularly well-defined process of leukemic progression. 
MOUSE MODEL TO STUDY THE IMPACT OF Csf3r 
AND RUNX1 MUTATIONS IN CONJUNCTION WITH 
CSF3 TREATMENT 
The impact of Runx1 and mutants on hematopoietic cell 
development has been investigated in a variety of mouse 
models and has been the subject of several recent reviews 
(Bellissimo and Speck, 2017; Chin et al., 2015; Harada and 
Harada, 2009; Sood et al., 2017). Notwithstanding some 
contradictory results, possibly related to discrepancies in the 
immune-phenotyping based classification of stem cell sub-
populations, it is generally accepted that wild type Runx1 has 
no major impact on the production and function of long-
term hematopoietic stem cells in mice, both under homeo-
static conditions and under conditions of proliferative stress 
(Cai et al., 2011). More relevant in the context of RUNX1 
mutations in SCN-MDS/AML are the mouse models with 
RUNX1-RHD mutations equivalent to those recurrently found 
in patients (Harada et al., 2004). Watanabe-Okochi and 
colleagues studied the effects of such a mutant in transplan-
tation experiments, in which donor bone marrow (BM) cells 
were transduced with a murine leukemia virus (MLV)-derived 
vector to express the most common RUNX1 mutant D171N 
and reported that this resulted in MDS and MDS/AML (Wata-
nabe-Okochi et al., 2008). However, integration of the MLV-
based vector in the Mecom (Evi1) locus caused overexpres-
sion of Evi1 in these mice (Watanabe-Okochi et al., 2008). 
Because the combination of RUNX1 mutations and high EVI1 
expression is rarely seen in MDS/AML, and because high Evi1 
expression can be leukemogenic by itself, the contribution 
of RUNX1-RHD in MDS/AML development in more general 
could not be accurately deduced from this model (Harada et 
al., 2013; Watanabe-Okochi et al., 2008). In fact, expression 
of mutant D171N in human cord blood cells had marginal ef-
fects on the rate of proliferation and differentiation capacity 
of CD34+ cells in in vitro suspension culture relative to empty 
vector control cells, suggesting that isolated RUNX-RHD mu-
tations are only weakly leukemogenic (Goyama et al., 2013). 
 To study the role of RUNX1-D171N in a context relevant 
to SCN-MDS/AML, we used a mouse model expressing a 
truncated Csf3r (Csf3r-d715) identical to the mutant CSF3R 
form in SCN patients (Hermans et al., 1998; 1999). To avoid 
the tropism of MLV-based vectors for oncogenic enhancers, 
we generated a lentiviral expression vector to express RUNX1 
mutant D171N (Goyama et al., 2013) in conjunction with 
enhanced green fluorescent protein (eGFP) in Csf3r-d715 
BM cells, which were subsequently serially transplanted in 
wild type recipients. Recipients were treated either 3× a week 
with CSF3 or with PBS (solvent control). Transcriptome analy-
sis and whole exome sequencing on FACS purified eGFP+Lin–
c-Kit+ (LK) populations were done to identify molecular path-
ways associated with leukemic progression. Sequential CD34+ 
cell samples from a SCN/AML patient with identical CSF3R 
and RUNX1 mutations (Beekman et al., 2012) and whole 
genome sequencing data from diagnostic AML samples were 
used for clinical comparisons (Olofsen et al., 2018).
 CSF3 treatment of primary recipients transplanted with 
Csf3r-RUNX1 mutant BM cells resulted in sustained (30+ 
weeks) presence of eGFP+LK cells in the peripheral blood 
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(PB), which had the morphological appearance of myelo-
blasts. The PB also contained eGFP+ neutrophils, indicating 
that myeloid differentiation was not completely blocked. Im-
portantly, none of these primary recipient mice succumbed to 
symptoms of AML, suggesting that the elevated myeloblasts 
in the PB reflected a pre-leukemic rather than a fully trans-
formed state. However, upon transplantation in secondary 
and tertiary recipients, mice developed Csf3r-RUNX1 mutant 
AML that was no longer dependent on CSF3 administration. 
Transcriptome profiles of purified eGFP+LK cells sorted before 
transplantation, showed that expression of RUNX1 mutant 
protein in Csf3r mutant cells resulted in elevated proliferative/
metabolic signatures characterized by elevated MYC and 
mTORC1 signaling relative to empty vector controls. Strik-
ingly, at the sequential steps of leukemic transformation in 
the mouse model, these signatures declined while TNFα-, 
interferon- and interleukin-6–driven inflammatory responses 
were increasingly upregulated. Whole exome sequencing 
performed on the LK-cells from these stages revealed that an 
internal tandem duplication (ITD) in Cxxc4 was acquired. In 
the secondary and tertiary recipients all AML cells harbored 
the Csf3r, RUNX1 and heterozygous Cxxc4 mutations, while 
the primary recipient showed a subclonal Cxxc4 mutation 
(VAF: 0.27). The mutation resulted in a 7-fold higher ex-
pression of CXXC4 protein. CXXC4 was previously shown 
to inhibit TET2 protein levels (Hino et al., 2001; Ko et al., 
2013) and in agreement with this, TET2 levels were strongly 
reduced in the CXXC4 mutant/overexpressing leukemic sam-
ples. Intriguingly, CXXC4 mutations have also been detected 
in human AML cases, including the ITD mutations identified 
in our mouse model (Olofsen et al., 2018; Olofsen et al., 
Unpublished reference). These observations in mice fit into a 
model in which the activation of a truncated Csf3r by the sus-
tained administration of CSF3 and the presence of RUNX1-
RHD mutant D171N give rise to a premalignant state, charac-
terized by the accumulation of LK cells in the PB and elevated 
activation of proliferative signalling (Fig. 1). An additional 
clonal mutation that reduces the levels of TET2 drives the full 
transformation to AML, at which stage the leukemia-initiat-
ing cells have lost their need for CSF3 for propagation in vivo 
and the AML blasts have adopted an inflammatory signature 
identical to that of SCN/AML cells with identical mutations in 
CSF3R and RUNX1 (Fig. 1) (Beekman et al., 2012; Schmied 
et al., Unpublished reference). Although CXXC4 mutations 
have thus far not been reported in clinical SCN/AML samples, 
mutations potentially affecting TET2 levels and/or function, 
such as mutations in polycomb repressor complex-2 genes 
(EZH2, SUZ12) are recurrently present (Beekman et al., 2012; 
Skokowa et al., 2014).    
STUDIES IN INDUCED PLURIPOTENT STEM CELL 
(iPSC) MODELS
The use of patient-derived iPSC lines has created new pos-
sibilities to model diseases, including myeloid malignancies 
(Papapetrou, 2019). In the context of RUNX1, these studies 
have mainly dealt with FPD/AML, characterized by germline 
RUNX1 mutations (Antony-Debre et al., 2015; Connelly et al., 
2014; Sakurai et al., 2014). Key features of these iPSC lines 
are (i) their reduced ability to generate CD34+CD45+ hemato-
poietic stem and progenitor cells (HSPCs) and (ii) their affect-
ed ability of megakaryocyte (Mk) production and pro-platelet 
formation, thus explaining the platelet defects observed in 
patients. The reduced production of HSPCs from FPD-derived 
iPSCs is consistent with a role of RUNX1 in hematopoietic 
development from pluripotent stem cells (Yzaguirre et al., 
2017). As mentioned above, in SCN patients who develop 
MDS or AML, RUNX1 mutations are most often acquired 
in CSF3R mutant HSPC clones. Hence, it is important in this 
context to assess the consequences of somatic RUNX1 mu-
tations in HSPCs cells that already harbor a CSF3R nonsense 
mutation. To achieve this, a CRISPR/Cas9-based strategy was 
used to introduce a patient-derived CSF3R nonsense muta-
tion into iPSCs. After switching the cells to hematopoietic 
culture conditions (STEMdiff Hematopoietic Kit from STEM-
CELL Technologies, Canada), CD34+CD45+ cells were lentivi-
rally transduced to express the RUNX1-RHD D171N mutant. 
These experiments showed that the combined presence of 
CSF3R and RUNX1 mutations had a moderate effect on my-
eloid differentiation, characterized by a relative abundance 
of immature neutrophilic differentiation stages, but not by 
an absolute differentiation block (Fig. 2). As such, these find-
ings corroborate the findings in the mouse model described 
above and further suggest that secondary RUNX1 mutations 
in clones with CSF3R mutations do not confer a fully trans-
formed, i.e., MDS/AML like phenotype. In agreement with 
this, transcriptome analysis showed that the CSF3R-RUNX1 
mutant cells had elevated proliferative signatures but did not 
show the inflammatory profiles seen in the SCN/AML patient 
and the mouse AML cells. A key question that remains to 
be addressed is how mutations in ELANE, HAX1 and other 
Fig. 1. Model of leukemic progression in mice based on serial 
transplantation of Csf3r-d715/RUNX1-RHD mutant BM cells. In 
primary recipients, the combination of Csf3r-d715 and RUNX1-
D171N gives rise to accumulation of immature LK cells. This 
occurs only when mice are treated with G-CSF (CSF3) and mice 
do not succumb to symptoms of leukemia. Upon secondary 
and subsequent transplantations of these LK cells, a G-CSF 
independent AML develops, which is characterized by elevated 
inflammatory responses and reduced TET2 protein levels.
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SCN-causing mutations contribute to leukemic progression in 
conjunction with CSF3R and RUNX1 mutations. Preliminary 
data from these models suggest that ELANE and HAX1 mu-
tations cause elevated levels of ROS in CD34+CD45+ HSPCs 
generated from SCN-iPSCs, resulting in the upregulation of 
anti-oxidant pathways (Olofsen et al., 2019). Future work 
should clarify whether and to what extent the oxidative dam-
age caused by ROS and the adaptive anti-oxidant protection 
mechanisms contribute to malignant transformation. 
CONCLUSIONS AND OUTLOOK
The role of RUNX1 mutations in the development of MDS 
and AML remains incompletely understood. Studies in 
mouse-, patient- and iPSC-models, addressing the role of a 
recurrent RUNX1 mutation (D171N) in combination with the 
most frequent CSF3R mutation in the leukemic progression 
of SCN (CSF3R-d715), showed that RUNX1-D171N enhanced 
the activation of proliferative signaling pathways but only 
mildly affected myeloid differentiation, leading to a relative 
accumulation of immature cells but not to an absolute dif-
ferentiation block. Furthermore, the studies in mice showed 
that the combination of these two mutations is not enough 
for leukemic progression, even when the mice were sub-
jected to sustained G-CSF (CSF3) treatment. These findings 
established that additional events, one of which affecting 
TET2 levels, are necessary for full leukemic transformation. 
Leukemic progression in all models was also associated with 
enhanced interferon-γ, interleukin-6 and TNFα/NFkB signal-
ing, suggesting that inflammation is a major additional com-
ponent in the development of myeloid malignancy involving 
RUNX1 mutations. How this interplay between mutant 
CSF3R signaling, aberrant transcriptional control by mutant 
RUNX1, loss of TET2 function and inflammatory responses 
contributes to leukemic transformation and what the exact 
causal relationships between these mechanisms are remains 
to be addressed. Detailed insights into this complex network 
of events may help to discover biomarkers for early detection 
of leukemic progression of SCN and possibly other forms of 
iBMFs and may provide leads for novel forms of therapeutic 
intervention to avoid full malignant transformation of these 
conditions. 
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Fig. 2. Myeloid differentiation of iPSC-derived CD34+CD45+ cells, genome-edited to express a truncated form (d715) of CSF3R and 
transduced with RUNX1-D171N lentiviral expression vector or empty vector (ev) control. Cells were cultured in suspension for a total of 
9 days in medium supplemented with myeloid growth factors, i.e., a cocktail of IL3, SCF, GM-CSF and G-CSF for the first 4 days, followed 
by G-CSF as the single growth factor for the next 5 days.  
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